Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Dominic M. Walsh, Igor Klyubin, Julia V. Fadeeva, William K. Cullen, Roger Anwyl, Michael S. Wolfe, Michael J. Rowan and Dennis J. Selkoe ()
Additional contact information
Dominic M. Walsh: Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital
Igor Klyubin: Trinity College
Julia V. Fadeeva: Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital
William K. Cullen: Trinity College
Roger Anwyl: Trinity College
Michael S. Wolfe: Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital
Michael J. Rowan: Trinity College
Dennis J. Selkoe: Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital

Nature, 2002, vol. 416, issue 6880, 535-539

Abstract: Abstract Although extensive data support a central pathogenic role for amyloid β protein (Aβ) in Alzheimer's disease1, the amyloid hypothesis remains controversial, in part because a specific neurotoxic species of Aβ and the nature of its effects on synaptic function have not been defined in vivo. Here we report that natural oligomers of human Aβ are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell. Cerebral microinjection of cell medium containing these oligomers and abundant Aβ monomers but no amyloid fibrils markedly inhibited hippocampal long-term potentiation (LTP) in rats in vivo. Immunodepletion from the medium of all Aβ species completely abrogated this effect. Pretreatment of the medium with insulin-degrading enzyme, which degrades Aβ monomers but not oligomers, did not prevent the inhibition of LTP. Therefore, Aβ oligomers, in the absence of monomers and amyloid fibrils, disrupted synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid. Finally, treatment of cells with γ-secretase inhibitors prevented oligomer formation at doses that allowed appreciable monomer production, and such medium no longer disrupted LTP, indicating that synaptotoxic Aβ oligomers can be targeted therapeutically.

Date: 2002
References: Add references at CitEc
Citations: View citations in EconPapers (8)

Downloads: (external link)
https://www.nature.com/articles/416535a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:416:y:2002:i:6880:d:10.1038_416535a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/416535a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().